{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:13:59Z","timestamp":1789913639974,"version":"4.0.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00288","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T04:33:57Z","timestamp":1551328437000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of Leishmania (Leishmania) donovani"],"prefix":"10.3389","volume":"10","author":[{"given":"Sumit","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerti","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amogh Anant","family":"Sahasrabuddhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Imran","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahajul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1086\/320994","article-title":"Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure","volume":"184","author":"Hailu","year":"2001","journal-title":"J Infect Dis"},{"key":"B2","unstructured":"Leishmaniasis2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/trstmh\/trv039","article-title":"Development of Leishmania vaccines in the era of visceral leishmaniasis elimination","volume":"109","author":"Engwerda","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1016\/j.vaccine.2015.12.071","article-title":"Status of vaccine research and development of vaccines for leishmaniasis","volume":"34","author":"Gillespie","year":"2016","journal-title":"Vaccine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1016\/j.vaccine.2015.06.117","article-title":"New approaches to understanding the immune response to vaccination and infection","volume":"33","author":"Furman","year":"2015","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the use of peptides in vaccine design","volume":"6","author":"Purcell","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"B8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/35105075","article-title":"Strategies for designing and optimizing new generation vaccines","volume":"1","author":"Berzofsky","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1440-1711.2002.01092.x","article-title":"Immuno-informatics: mining genomes for vaccine components","volume":"80","author":"De Groot","year":"2002","journal-title":"Immunol Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1128\/IAI.00533-10","article-title":"Multiple antigen peptide vaccines against Plasmodium falciparum malaria","volume":"78","author":"Mahajan","year":"2010","journal-title":"Infect Immun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4161\/hv.6.1.9601","article-title":"The past decade in malaria synthetic peptide vaccine clinical trials","volume":"6","author":"Nardin","year":"2010","journal-title":"Hum Vacc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1016\/j.vaccine.2014.04.026","article-title":"A synthetic peptide from Trypanosomacruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease","volume":"32","author":"Serna","year":"2014","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1756-3305-6-125","article-title":"Screening and identification of novel B cell epitopes of Toxoplasma gondii SAG1","volume":"6","author":"Wang","year":"2013","journal-title":"Parasit Vect"},{"key":"B14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/35021239","article-title":"Vaccines against intracellular infections requiring cellular immunity","volume":"406","author":"Seder","year":"2000","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"234fs18","DOI":"10.1126\/scitranslmed.3009118","article-title":"Using humans to make a human leishmaniasis vaccine","volume":"6","author":"Kamhawi","year":"2014","journal-title":"Sci Transl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5700","DOI":"10.1016\/j.vaccine.2008.08.021","article-title":"Th1-stimulatory polyproteins of soluble Leishmaniadonovani promastigotes ranging from 89","volume":"26","author":"Kumari","year":"2008","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fmicb.2016.00312","article-title":"Comparative analysis of cellular immune responses in treated Leishmania patients and hamsters against recombinant th1 stimulatory proteins of Leishmaniadonovani","volume":"7","author":"Joshi","year":"2016","journal-title":"Front Microbiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e86073","DOI":"10.1371\/journal.pone.0086073","article-title":"Characterization of glycolytic enzymes-rAldolase and rEnolase of Leishmaniadonovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis","volume":"9","author":"Gupta","year":"2014","journal-title":"PLoS ONE"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.4049\/jimmunol.1102081","article-title":"Elongation factor-2, a Th1 stimulatory protein of Leishmaniadonovani, generates strong IFN-gamma and IL-12 response in cured Leishmania-infected patients\/hamsters and protects hamsters against Leishmania challenge","volume":"187","author":"Kushawaha","year":"2011","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ijpara.2012.02.013","article-title":"A novel recombinant Leishmaniadonovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis","volume":"42","author":"Gupta","year":"2012","journal-title":"Int J Parasitol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e35670","DOI":"10.1371\/journal.pone.0035670","article-title":"Evaluation of Leishmaniadonovani protein disulfide isomerase as a potential immunogenic protein\/vaccine candidate against visceral Leishmaniasis","volume":"7","author":"Kushawaha","year":"2012","journal-title":"PLoS ONE"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e45766","DOI":"10.1371\/journal.pone.0045766","article-title":"Leishmaniadonovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis","volume":"7","author":"Kushawaha","year":"2012","journal-title":"PLoS ONE"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1126\/science.7403880","article-title":"Human cutaneous leishmania in a mouse macrophage line: propagation and isolation of intracellular parasites","volume":"209","author":"Chang","year":"1980","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2249.2005.02745.x","article-title":"Immunostimulatory cellular responses0020of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani","volume":"40","author":"Garg","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/eji.200838389","article-title":"Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmaniaamazonensis elicits immunity against visceral leishmaniasis","volume":"39","author":"Kumari","year":"2009","journal-title":"Eur J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/ng.2518","article-title":"Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis","volume":"45","author":"Fakiola","year":"2013","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1586\/14760584.6.4.591","article-title":"Design and development of synthetic peptide vaccines: past, present and future","volume":"6","author":"Bijker","year":"2007","journal-title":"Exp Rev Vacc"},{"key":"B29","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide vaccine: progress and challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fimmu.2014.00380","article-title":"Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches","volume":"5","author":"Joshi","year":"2014","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3389\/fimmu.2018.01043","article-title":"Peptide vaccines for leishmaniasis","volume":"9","author":"De Brito","year":"2018","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-genom-091212-153455","article-title":"Major histocompatibility complex genomics and human disease","volume":"14","author":"Trowsdale","year":"2013","journal-title":"Ann Rev Genom Human Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3389\/fimmu.2017.00832","article-title":"Human leukocyte antigen (HLA) and immune regulation: how do classical and non-classical hla alleles modulate immune response to human immunodeficiency virus and hepatitis c virus infections?","volume":"8","author":"Crux","year":"2017","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.2174\/138161209789105171","article-title":"HLA-DR: molecular insights and vaccine design","volume":"15","author":"Stern","year":"2009","journal-title":"Curr Pharm Design"},{"key":"B36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fimmu.2013.00421","article-title":"CD4(+) T cell priming as biomarker to study immune response to preventive vaccines","volume":"4","author":"Ciabattini","year":"2013","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ijpara.2012.02.013","article-title":"A novel recombinant Leishmaniadonovanip45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis","volume":"42","author":"Gupta","year":"2012","journal-title":"Int J Parasitol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1128\/CVI.00143-12","article-title":"Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood","volume":"6","author":"Singh","year":"2012","journal-title":"Clin Vacc Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1586\/14760584.2015.1068124","article-title":"Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy","volume":"14","author":"Zheng","year":"2015","journal-title":"Exp Rev Vacc"},{"key":"B40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S1674-8301(10)60004-8","article-title":"A review of adjuvants for Leishmania vaccine candidates","volume":"24","author":"Joshua","year":"2010","journal-title":"J Biomed Res"},{"key":"B41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D32FW0G1XX","article-title":"Delayed type hypersensitivity: current theories with an historic perspective","volume":"5","author":"Black","year":"1999","journal-title":"Dermatol Online J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13071-016-1412-x","article-title":"Regulation of immunity during visceral Leishmania infection","volume":"9","author":"Rodrigues","year":"2016","journal-title":"Parasit Vect"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.4049\/jimmunol.166.3.1912","article-title":"The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response","volume":"166","author":"Melby","year":"2001","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.4049\/jimmunol.1003588","article-title":"IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis","volume":"186","author":"Ansari","year":"2011","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat Rev Genet"},{"key":"B46","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4049\/jimmunol.153.2.768","article-title":"Role and effect of TNF-alpha in experimental visceral leishmaniasis","volume":"153","author":"Tumang","year":"1994","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.4049\/jimmunol.170.5.2613","article-title":"Activation of TGF-beta by Leishmaniachagasi: importance for parasite survival in macrophages","volume":"170","author":"Gantt","year":"2003","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1038\/s41598-017-04595-8","article-title":"Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance","volume":"7","author":"Ara\u00fajo-Santos","year":"2017","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00288\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:37:18Z","timestamp":1694651838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00288\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2019.00288"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00288","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"article-number":"288"}}